NCT07479862

A Study of SA030 Injection in Overweight or Obese Participants

A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SA030 Injection in Overweight or Obese Participants

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Suzhou Siran Biotechnology Co.,Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight or obese. Over the last few decades, more and more people around the world have become overweight or obese, and the numbers keep rising in almost every country. From 1990 to 2021, this problem grew steadily and reached its highest point in 2021.

Conditions

• Obese
• Overweight

Interventions

Type	Name	Description
DRUG	Dose escalation of SA030	Single dose, 5 dose levels
DRUG	Matching placebo of SA030	Arm 2. single dose, matching placebo

Timeline

• Start date: 2026-04-16
• Primary completion: 2026-08-18
• Completion: 2027-03-03
• First posted: 2026-03-18
• Last updated: 2026-03-18

Locations

1 site across 1 country: Australia